This post was originally published on this site

Five years after Novartis stepped up with a sizable deal that gave them worldwide rights to Surface Oncology’s lead cancer drug, GlaxoSmithKline is coming in at the other end of the pipeline, snagging a preclinical natural killer drug designed to whip up a more effective attack on cancer cells. Read more.

The post GlaxoSmithKline plumbs the discovery field (again), betting up to $815M for the latest add-on to its oncology pipeline appeared first on Atlas Venture.